左心室辅助装置植入术中机械性右心室支持的策略
基于胸外科医师学会国家数据库2011至2019年18423例首次耐久型左心室辅助装置植入患者,其中940例(5.1%)需要右心室辅助装置或静脉-动脉体外膜氧合支持。倾向性评分校正后,静脉-动脉体外膜氧合支持者死亡风险高于右心室辅助装置(风险比1.46,95%CI 1.21至1.77,P<.01);术后启动右心室支持者死亡风险高于术中启动(风险比1.43,P<.01)。
要点
- 耐久型左心室辅助装置植入患者中5.1%需右心室辅助装置或静脉-动脉体外膜氧合支持。
- 静脉-动脉体外膜氧合支持者死亡风险约为右心室辅助装置者的1.46倍(95%CI 1.21至1.77)。
- 术后启动右心室支持者死亡风险高于术中启动者(风险比1.43,P<.01)。
核心结论
- 耐久型左心室辅助装置植入时发生严重右心室衰竭的患者,使用右心室辅助装置可能优于静脉-动脉体外膜氧合。
- 无论采用何种支持类型,在本次手术中启动支持与改善结局相关。
研究设计与样本
- 回顾性分析胸外科医师学会国家数据库2011至2019年首次耐久型左心室辅助装置植入患者。
- 共纳入18423例左心室辅助装置植入患者,其中940例(5.1%)需要右心室辅助装置(n=750)或静脉-动脉体外膜氧合(n=190)支持。
- 患者按右心室辅助装置或静脉-动脉体外膜氧合分组,并按置入时机(术中与术后)分层。
主要发现
- 右心室辅助装置组术前需要正性肌力药物者占76%,静脉-动脉体外膜氧合组占62%(P<.01)。
- 右心室辅助装置组严重三尖瓣反流者占20%,静脉-动脉体外膜氧合组占13%(P<.01)。
- 右心室辅助装置组术后肾衰竭发生率为40%,静脉-动脉体外膜氧合组为51%(P=.02)。
- 右心室辅助装置组肢体缺血发生率为4%,静脉-动脉体外膜氧合组为13%(P<.01)。
- 右心室辅助装置组手术死亡率为41%,静脉-动脉体外膜氧合组为54%(P<.01),右心室辅助装置组显著更低。
临床怎么用
- 作者认为,耐久型左心室辅助装置植入时发生严重右心室衰竭的患者,使用右心室辅助装置可能优于静脉-动脉体外膜氧合。
- 作者认为,无论采用何种支持类型,在本次手术中启动支持与改善结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Refractory right ventricular failure at the time of left ventricular assist device implantation requires treatment with supplemental mechanical circulatory support. However, the optimal strategy for support remains unknown. METHODS: All patients undergoing first-time durable left ventricular assist device implantation with a contemporary device were selected from The Society of Thoracic Surgeons National Database (2011 to 2019). Patients requiring right ventricular assist device (RVAD) or venoarterial extracorporeal membrane oxygenation (VA-ECMO) were included in the analysis. Patients were stratified by RVAD or VA-ECMO and by timing of placement (intraoperative vs postoperative). RESULTS: In all, 18 423 left ventricular assist device implants were identified, of which 940 (5.1%) required RVAD (n = 750) or VA-ECMO (n = 190) support. Patients receiving an RVAD more frequently had preoperative inotrope requirement (76% vs 62%, P < .01) and severe tricuspid regurgitation (20% vs 13%, P < .01). The RVAD patients had lower rates of postoperative renal failure (40% vs 51%, P = .02) and limb ischemia (4% vs 13%, P < .01), as well as significantly less operative mortality (41% vs 54%, P < .01). After risk adjustment with propensity score analysis, support with VA-ECMO was associated with a higher risk of mortality (risk ratio 1.46; 95% confidence interval, 1.21 to 1.77; P < .01) compared with patients receiving an RVAD. Importantly, institution of right ventricular support postoperatively was associated with higher mortality (1.43, P < .01) compared with intraoperative initiation. CONCLUSIONS: Patients with severe right ventricular failure in the setting of durable left ventricular assist device implantation may benefit from the use of RVAD over VA-ECMO. Regardless of the type of support, initiation at the index operation was associated with improved outcomes.
引用
- Beller JP, Mehaffey JH, Wegermann ZK, et al. Strategies for Mechanical Right Ventricular Support During Left Ventricular Assist Device Implant. Ann Thorac Surg. 2021. PMID: 34843696. doi:10.1016/j.athoracsur.2021.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。